Featured Publications
Salimando et al. Nature Communications. 2023
With concurrent global epidemics of chronic pain and opioid use disorders, there is a critical need to identify, target and manipulate specific cell populations expressing the mu-opioid receptor (MOR). However, available tools and transgenic models for gaining long-term genetic access to MOR+ neural cell types and circuits involved in modulating pain, analgesia and addiction across species are limited. To address this, we developed a catalog of MOR promoter (MORp) based constructs packaged into adeno-associated viral vectors that drive transgene expression in MOR+ cells. MORp constructs designed from promoter regions upstream of the mouse Oprm1 gene (mMORp) were validated for transduction efficiency and selectivity in endogenous MOR+ neurons in the brain, spinal cord, and periphery of mice, with additional studies revealing robust expression in rats, shrews, and human induced pluripotent stem cell (iPSC)-derived nociceptors. The use of mMORp for in vivo fiber photometry, behavioral chemogenetics, and intersectional genetic strategies is also demonstrated. Lastly, a human designed MORp (hMORp) efficiently transduced macaque cortical OPRM1+ cells. Together, our MORp toolkit provides researchers cell type specific genetic access to target and functionally manipulate mu-opioidergic neurons across a range of vertebrate species and translational models for pain, addiction, and neuropsychiatric disorders.
An amygdalar neural ensemble that encodes the unpleasantness of pain
Pain is an unpleasant experience. How the brain’s affective neural circuits attribute this aversive quality to nociceptive information remains unknown. By means of time-lapse in vivo calcium imaging and neural activity manipulation in freely behaving mice encountering noxious stimuli, we identified a distinct neural ensemble in the basolateral amygdala that encodes the negative affective valence of pain. Silencing this nociceptive ensemble alleviated pain affective-motivational behaviors without altering the detection of noxious stimuli, withdrawal reflexes, anxiety, or reward. Following peripheral nerve injury, innocuous stimuli activated this nociceptive ensemble to drive dysfunctional perceptual changes associated with neuropathic pain, including pain aversion to light touch (allodynia). These results identify the amygdalar representations of noxious stimuli that are functionally required for the negative affective qualities of acute and chronic pain perception.
Corder et al. Nature Medicine 2017 (cover)
Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH). Tolerance and OIH counteract opioid analgesia and drive dose escalation. The cell types and receptors on which opioids act to initiate these maladaptive processes remain disputed, which has prevented the development of therapies to maximize and sustain opioid analgesic efficacy. We found that μ opioid receptors (MORs) expressed by primary afferent nociceptors initiate tolerance and OIH development. RNA sequencing and histological analysis revealed that MORs are expressed by nociceptors, but not by spinal microglia. Deletion of MORs specifically in nociceptors eliminated morphine tolerance, OIH and pronociceptive synaptic long-term potentiation without altering antinociception. Furthermore, we found that co-administration of methylnaltrexone bromide, a peripherally restricted MOR antagonist, was sufficient to abrogate morphine tolerance and OIH without diminishing antinociception in perioperative and chronic pain models. Collectively, our data support the idea that opioid agonists can be combined with peripheral MOR antagonists to limit analgesic tolerance and OIH.
Constitutive μ-Opioid Receptor Activity Leads to Long-Term Endogenous Analgesia and Dependence
Corder et al. Science. 2013 (cover)
Opioid receptor antagonists increase hyperalgesia in humans and animals, which indicates that endogenous activation of opioid receptors provides relief from acute pain; however, the mechanisms of long-term opioid inhibition of pathological pain have remained elusive. We found that tissue injury produced μ-opioid receptor (MOR) constitutive activity (MORCA) that repressed spinal nociceptive signaling for months. Pharmacological blockade during the posthyperalgesia state with MOR inverse agonists reinstated central pain sensitization and precipitated hallmarks of opioid withdrawal (including adenosine 3′,5′-monophosphate overshoot and hyperalgesia) that required N-methyl-D-aspartate receptor activation of adenylyl cyclase type 1. Thus, MORCA initiates both analgesic signaling and a compensatory opponent process that generates endogenous opioid dependence. Tonic MORCA suppression of withdrawal hyperalgesia may prevent the transition from acute to chronic pain.
Structure-based discovery of opioid analgesics with reduced side effects
Manglik et al. Nature. 2016
Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids—which include fatal respiratory depression—are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors. Conversely, G-protein μOR signalling is thought to confer analgesia. Here we computationally dock over 3 million molecules against the μOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21—a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.
Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits
Wang et al. Neuron. 2018 (cover)
Cellular interactions between delta and mu opioid receptors (DORs and MORs), including heteromerization, are thought to regulate opioid analgesia. However, the identity of the nociceptive neurons in which such interactions could occur in vivoremains elusive. Here we show that DOR-MOR co-expression is limited to small populations of excitatory interneurons and projection neurons in the spinal cord dorsal horn and unexpectedly predominates in ventral horn motor circuits. Similarly, DOR-MOR co-expression is rare in parabrachial, amygdalar, and cortical brain regions processing nociceptive information. We further demonstrate that in the discrete DOR-MOR co-expressing nociceptive neurons, the two receptors internalize and function independently. Finally, conditional knockout experiments revealed that DORs selectively regulate mechanical pain by controlling the excitability of somatostatin-positive dorsal horn interneurons. Collectively, our results illuminate the functional organization of DORs and MORs in CNS pain circuits and reappraise the importance of DOR-MOR cellular interactions for developing novel opioid analgesics.
Endogenous and exogenous opioids in pain
Corder, Castro, Bruchas, Scherrer. Annual Review of Neuroscience. July 2018
Opioids are the most commonly used and effective analgesic treatments for severe pain, but they have recently come under scrutiny owing to epidemic levels of abuse and overdose. These compounds act on the endogenous opioid system, which comprises four G protein–coupled receptors (mu, delta, kappa, and nociceptin) and four major peptide families (β-endorphin, enkephalins, dynorphins, and nociceptin/orphanin FQ). In this review, we first describe the functional organization and pharmacology of the endogenous opioid system.We then summarize current knowledge on the signaling mechanisms by which opioids regulate neuronal function and neurotransmission. Finally, we discuss the loci of opioid analgesic action along peripheral and central pain pathways, emphasizing the pain-relieving properties of opioids against the affective dimension of the pain experience.
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA
Linguiti et al. Neuroscience & Biobehavioral Reviews. 2022
Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. While fMRI is a promising tool for measuring brain function in response to psychedelics, it also has known methodological challenges. We conducted a systematic review of fMRI studies examining acute responses to experimentally administered psychedelics in order to identify convergent findings and characterize heterogeneity in the literature. We reviewed 91 full-text papers; these studies were notable for substantial heterogeneity in design, task, dosage, drug timing, and statistical approach. Data recycling was common, with 51 unique samples across 91 studies. Fifty-seven studies (54%) did not meet contemporary standards for Type I error correction or control of motion artifact. Psilocybin and LSD were consistently reported to moderate the connectivity architecture of the sensorimotor-association cortical axis. Studies also consistently reported that ketamine administration increased activation in the dorsomedial prefrontal cortex. Moving forward, use of best practices such as pre-registration, standardized image processing and statistical testing, and data sharing will be important in this rapidly developing field.
PREPRINTS
Mimicking opioid analgesia in cortical pain circuits. Justin G. James, Nora M. McCall, Alex I. Hsu, Corinna S. Oswell, Gregory J. Salimando, Malaika Mahmood, Lisa M. Wooldridge, Meghan Wachira, Adrienne Jo, Raquel Adaia Sandoval Ortega, Jessica A. Wojick, Katherine Beattie, Sofia A. Farinas, Samar N. Chehimi, Amrith Rodrigues, Lindsay L. Ejoh, Blake A. Kimmey, Emily Lo, Ghalia Azouz, Jose J. Vasquez, Matthew R. Banghart, Kate Townsend Creasy, Kevin T. Beier, Charu Ramakrishnan, Richard C. Crist, Benjamin C. Reiner, Karl Deisseroth, Eric A. Yttri, Gregory Corder. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.04.26.591113v1
A nociceptive amygdala-striatal pathway for chronic pain aversion. Jessica A. Wojick, Alekh Paranjapye, Juliann K. Chiu, Malaika Mahmood, Corinna Oswell, Blake A. Kimmey, Lisa M. Wooldridge, Nora M. McCall, Alan Han, Lindsay L. Ejoh, Samar Nasser Chehimi, Richard C. Crist, Benjamin C. Reiner, Erica Korb, Gregory Corder. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.02.12.579947v1
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles. Sophie A. Rogers, Elizabeth A. Heller, Gregory Corder. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.02.04.578811v2
VTA µ–opioidergic neurons facilitate low sociability in protracted opioid withdrawal. Adrienne Jo, Yihan Xie, Amrith Rodrigues, Raquel Adaia Sandoval Ortega, Kate Townsend Creasy, Kevin T. Beier, Julie A. Blendy, Gregory Corder. bioRxiv. 2024
AxoDen: An algorithm for the automated quantification of axonal density in defined brain regions. Raquel Adaia Sandoval Ortega, Emmy Li, Oliver Joseph, Pascal A. Dufour, Gregory Corder. bioRxiv. 2024. https://www.biorxiv.org/content/10.1101/2024.05.30.596687v1
publications
* denotes equal contributions
Engineered serum markers for non-invasive monitoring of gene expression in the brain. Sangsin Lee, Shirin Nouraein, James J Kwon, Zhimin Huang, Jessica A Wojick, Boao Xia, Gregory Corder, Jerzy O Szablowski. Nature Biotechnology. 2024. https://www.nature.com/articles/s41587-023-02087-x
Human OPRM1 and murine Oprm1 promoter driven viral constructs for genetic access to μ-opioidergic cell types. Gregory J Salimando, Sébastien Tremblay, Blake A Kimmey, Jia Li, Sophie A Rogers, Jessica A Wojick, Nora M McCall, Lisa M Wooldridge, Amrith Rodrigues, Tito Borner, Kristin L Gardiner, Selwyn S Jayakar, Ilyas Singeç, Clifford J Woolf, Matthew R Hayes, Bart C De Jonghe, F Christian Bennett, Mariko L Bennett, Julie A Blendy, Michael L Platt, Kate Townsend Creasy, William R Renthal, Charu Ramakrishnan, Karl Deisseroth, Gregory Corder. Nature Communications. 2023. https://www.nature.com/articles/s41467-023-41407-2
Structural imaging studies of patients with chronic pain: an anatomical likelihood estimate meta-analysis. Alina T Henn, Bart Larsen, Lennart Frahm, Anna Xu, Azeez Adebimpe, J Cobb Scott, Sophia Linguiti, Vaishnavi Sharma, Allan I Basbaum, Gregory Corder, Robert H Dworkin, Robert R Edwards, Clifford J Woolf, Ute Habel, Simon B Eickhoff, Claudia R Eickhoff, Lisa Wagels, Theodore D Satterthwaite. Pain. 2023. https://journals.lww.com/pain/abstract/2023/01000/structural_imaging_studies_of_patients_with.5.aspx
A novel Oprm1-Cre mouse maintains endogenous expression, function and enables detailed molecular characterization of μ-opioid receptor cells. Juliet Mengaziol, Amelia D Dunn, Gregory Salimando, Lisa Wooldridge, Jordi Crues-Muncunill, Darrell Eacret, Chongguang Chen, Kathryn Bland, Lee-Yuan Liu-Chen, Michelle E Ehrlich, Gregory Corder, Julie A Blendy. PLOS One. 2022. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270317
Xu A, Larsen B, Henn A, Baller EB, Scott JC, Sharma V, Adebimpe A, Basbaum AI, Corder G, Dworkin RH, Edwards RR, Woolf CJ, Eickhoff SB, Eickhoff CR, Satterthwaite TD. Brain Responses to Noxious Stimuli in Patients With Chronic Pain: A Systematic Review and Meta-analysis. JAMA Network Open. 2021 Jan 4;4(1):e2032236. doi: 10.1001/jamanetworkopen.2020.32236. PMID: 33399857
Jones, J, Foster, W Twomey, C Burdge, J, Ahmed,O, Wojick JA, Corder G, Plotkin, JB, Abdus-Saboor, I. A machine-vision approach for automated pain measurement at millisecond timescales. eLife. 2020 Aug 6;9:e57258. doi: 10.7554/eLife.57258
Corder, G*, Ahanonu, B*, Grewe, B, Wang, D, Schnitzer, MJ, Scherrer, G. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science. 2019 Jan. 18; 363(6424):276-281. doi: 10.1126/science.aap8586. PMID: 3065440
Nelson TS, Fu W, Donahue RR, Corder GF, Hökfelt T, Wiley RG, Taylor BK. Facilitation of neuropathic pain by the NPY Y1 receptor-expressing subpopulation of excitatory interneurons in the dorsal horn. Scientific Reports. 2019 May 10;9(1):7248. doi: 10.1038/s41598-019-43493-z.
Corder, G*, Tawfik, VL*, Wang, D*, Sypek, ES*, Low, SA, Dickinson, JR, Sotoudeh, C, Clark, JD, Barres, B, Bohlen, C Scherrer, G. Loss of μ-opioid receptor signaling in nociceptors, and not spinal microglia, abrogates morphine tolerance without disrupting analgesia. Nature Medicine. 2017 Feb; 23(2):164-173. doi: 10.1038/nm.4262.
Wang, D, Tawfik, VL, Corder, G, Low, SA, Basbaum, AI, Scherrer, G. Functional Divergence of Delta and Mu Opioid Receptors Organization in CNS Pain Circuits. Neuron. 2018 Apr 4;98(1):90-108.e5. doi: 10.1016/j.neuron.2018.03.002.
Manglik, A*, Henry, L*, Aryal, DP*, McCorvy, JD, Dengler, D, Corder, G, Bernat, V, Huang, X, Sassano, MF, Giguere, PM, Levit, A, Lober, S, Hubner, H, Duan, D, Scherrer, G, Kobilka, BK, Gmeiner, P, Roth, BL, Shoichet, BK. Structure-based discovery of biased μ-opioid receptor analgesics with reduced side effects. Nature. 2016 Sep 8;537(7619):185-190. doi: 10.1038/nature19112.
Rowe R, Ellis G, Harrison J, Bachstetter A, Corder GF, Van Eldik L, Taylor BK, Marti F, Lifshitz J. Diffuse traumatic brain injury induces prolonged immune dysregulation and potentiates hyperalgesia following a peripheral immune challenge. Molecular Pain. 2016 May 13;12. doi: 10.1177/1744806916647055.
Taylor, BK, Fu, W, Kuphal, KE, Stiller, CO, Winter, MK, Chen, W, Corder, GF, Urban, JH, McCarson, KE, Marvizon, JC. Inflammation enhances Y1 receptor signaling, neuropeptide Y-mediated inhibition of hyperalgesia, and substance P release from primary afferent neurons. Neuroscience. 2014 Jan 3;256:178-94. doi: 10.1016/j.neuroscience.2013.10.054.
Corder, G, Doolen, S, Winter, MW, Jutras, BL, He, Y, Hu, X, Wieskopf, JS, Mogil, JS, Storm, DR, Wang, ZJ, McCarson, KE, Taylor, BK. Constitutive µ-opioid receptor activity leads to long-term endogenous analgesia and dependence. Science. 2013 Sep 20;341(6152):1394-9. doi: 10.1126/science.1239403.
Solway, BM, Bose, S, Corder, G, Donahue, R, Taylor, BK. Tonic inhibition of chronic pain by Neuropeptide Y. PNAS, USA. 2011 Apr 26;108(17):7224-9. doi: 10.1073/pnas.1017719108.
Corder, G, Siegel, A, Intondi, AB, Zhang, X, Zadina, JE, Taylor, BK. A novel method to quantify histochemical changes throughout the mediolateral axis of the substantia gelatinosa after spared nerve injury: characterization with TRPV1 and substance P. Journal of Pain. 2010 Apr;11(4):388-98. doi: 10.1016/j.jpain.2009.09.008.
Reviews / Book Chapters
Broadening our conceptual understanding of endogenous opioids in systems neuroscience. Hugo A Tejeda, Nicolas Massaly, Gregory Corder, Catherine M Cahill. Frontiers in Systems Neuroscience. 2023. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2023.1212650/full
Ahanonu, B, Corder, G. Chapter: Recording Pain-related Brain Activity in Behaving Animals using Calcium Imaging and Miniature Microscopes. Book: Contemporary approaches to the study of pain: from molecules to neural networks. Editor: Rebecca Seal. Publisher: Springer Nature. In Press.
Kimmey BA, McCall NM, Wooldridge LM, Satterthwaite TD, Corder G. Engaging endogenous opioid circuits in pain affective processes. Journal Neuroscience Research. 2020 Dec 13. doi: 10.1002/jnr.24762
McCall, N, Wojick, J, Corder, G. Anesthesia Analgesia in the Amygdala. Nature Neuroscience, News & Views. 2020 May. Doi: 10.1038/s41593-020-0645-3
Corder, G*, Castro, D*, Bruchas, M, Scherrer, G. Exogenous and endogenous opioids in pain. Annual Review of Neuroscience. 2018 Jul 8;41:453-473. doi: 10.1146/annurev-neuro-080317-061522.
Taylor, BK and Corder, G. Endogenous analgesia, dependence, and latent pain sensitization. Current Topics in Behavioral Neuroscience. 2014 Sep 17. doi 10.1007/7854_2014_351. PMID: 25227929.
Dissertation (s)
Corder, G. Injury Establishes Constitutive μ-Opioid Receptor Signaling Leading to Lasting Endogenous Analgesia and Dependence. University of Kentucky. 2013. http://uknowledge.uky.edu/physiology_etds/10/